文献速递冠心病

血流储备分数指导多支冠状动脉病变治疗

Fractional Flow Reserve to Guide Treatment of Patients With Multivessel Coronary Artery Disease.
PubMed 文献 · J Am Coll Cardiol · 2021-01-01

FUTURE试验为前瞻性随机开放标签优效性研究,将多支冠状动脉病变患者1:1随机分配至基于FFR的治疗策略或传统无FFR策略。1年随访时,两组主要不良心脑血管事件率无显著差异(14.6% vs 14.4%,HR 0.97,95%CI 0.69-1.36,P=0.85)。FFR组显著减少了血运重建患者比例,更多患者仅接受药物治疗(P=0.02)。

要点

  • FFR指导策略未降低1年主要不良心脑血管事件风险
  • FFR组全因死亡率3.7% vs 对照组1.5%,差异无统计学意义
  • FFR指导显著减少血运重建比例,更多患者仅药物治疗

核心结论

  • 在多支冠状动脉病变患者中,未发现FFR指导的治疗策略在1年随访时降低缺血性心血管事件或死亡风险的证据。

研究设计与样本

  • FUTURE试验为前瞻性、随机、开放标签优效性试验,纳入927例多支冠状动脉病变候选患者,1:1随机分配至基于FFR的治疗策略组或传统无FFR策略组。

主要发现

  • 1年随访时,意向性治疗分析显示两组主要不良心脑血管事件率无显著差异(FFR组14.6% vs 对照组14.4%;HR 0.97;95%CI 0.69-1.36;P=0.85)。
  • 全因死亡率差异无统计学意义(FFR组3.7% vs 对照组1.5%;HR 2.34;95%CI 0.97-5.18;P=0.06),24个月延长随访证实该结果。
  • FFR显著降低血运重建患者比例,更多患者仅接受药物治疗(P=0.02)。

关键数值与推荐

  • FFR组中,对狭窄≥50%的冠状动脉行FFR评估,FFR≤0.80的病变指示行血运重建(经皮冠状动脉介入或外科手术)。

临床怎么用

  • 在多支冠状动脉病变患者中,FFR指导策略可减少不必要的血运重建,但未显示改善1年临床预后。

局限性

  • 试验因数据安全监查委员会安全分析后提前终止,仅纳入927例患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is limited evidence that fractional flow reserve (FFR) is effective in guiding therapeutic strategy in multivessel coronary artery disease (CAD) beyond prespecified percutaneous coronary intervention or coronary graft surgery candidates. OBJECTIVES: The FUTURE (FUnctional Testing Underlying coronary REvascularization) trial aimed to evaluate whether a treatment strategy based on FFR was superior to a traditional strategy without FFR in the treatment of multivessel CAD. METHODS: The FUTURE trial is a prospective, randomized, open-label superiority trial. Multivessel CAD candidates were randomly assigned (1:1) to treatment strategy based on FFR in all stenotic (≥50%) coronary arteries or to a traditional strategy without FFR. In the FFR group, revascularization (percutaneous coronary intervention or surgery) was indicated for FFR ≤0.80 lesions. The primary endpoint was a composite of major adverse cardiac or cerebrovascular events at 1 year. RESULTS: The trial was stopped prematurely by the data safety and monitoring board after a safety analysis and 927 patients were enrolled. At 1-year follow-up, by intention to treat, there were no significant differences in major adverse cardiac or cerebrovascular events rates between groups (14.6% in the FFR group vs 14.4% in the control group; hazard ratio: 0.97; 95% confidence interval: 0.69-1.36; P = 0.85). The difference in all-cause mortality was nonsignificant, 3.7% in the FFR group versus 1.5% in the control group (hazard ratio: 2.34; 95% confidence interval: 0.97-5.18; P = 0.06), and this was confirmed with a 24 months' extended follow-up. FFR significantly reduced the proportion of revascularized patients, with more patients referred to exclusively medical treatment (P = 0.02). CONCLUSIONS: In patients with multivessel CAD, we did not find evidence that an FFR-guided treatment strategy reduced the risk of ischemic cardiovascular events or death at 1-year follow-up. (Functional Testing Underlying Coronary Revascularisation; NCT01881555).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Rioufol G, Dérimay F, Roubille F, et al. Fractional Flow Reserve to Guide Treatment of Patients With Multivessel Coronary Artery Disease. J Am Coll Cardiol. 2021. PMID: 34736563. doi:10.1016/j.jacc.2021.08.061

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。